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Abstract
Background: In last years Metabolic Syndrome (MetS) has been closely associated to Benign Prostatic Enlargement
(BPE) Aim of our study is to evaluate the effect of MetS and each single MetS parameter on prostate growth in
men surgically treated for BPE.
Methods: Overall, 379 men were prospectively enrolled in two tertiary referral centers. Calculated prostate volume (PV)
was measured with transrectal US defining the antero-posterior (AP), the cranio-caudal (CC) and the latero-lateral (LL)
diameters through the ellipsoid formula, while raw PV was calculated by suprapubic US. MetS was defined according
to the NCEP-ATPIII criteria.
Results: One-hundred and forty men (36.9%) were affected by MetS. The number of MetS parameters (0 to 5) and the
presence of MetS were correlated with the calculated PV. The number of MetS parameters were also directly related to
increasing prostate diameters. At the binary logistic regression, MetS resulted associated to high (>60 cc) raw and
calculated PV. Moreover, multivariate analysis suggested that AP diameter was mainly correlated with HDL cholesterol
(r:-0.3103, p = 0.002) CC diameter with triglycerides (r:-0.191, p = 0.050) and LL diameter with systolic blood
pressure (r:0.154, p = 0.044). However, at the binary logistic regression, only low HDL Cholesterol was the main
determinant for the enlargement of all diameters and consequently of the whole PV.
Conclusions: Metabolic factors, specially dyslipidemia, could play a central role in the pathogenesis and progression
of BPE/LUTS. Interventional studies are needed to evaluate the impact of early treatment of dyslipidemia on
progression of LUTS/BPH.
Keywords: Benign prostatic enlargement, Benign prostatic hyperplasia, Lower urinary tract symptoms,
Metabolic syndrome, Dyslipidemia
Background
Benign prostatic hyperplasia (BPH) is one of the most
common conditions among middle and advance-aged
men [1]. Autopsy studies revealed presence of BPH in
42% of men aged 51–60 year and 85% among men older
than 80 year; BPH is characterized by stromal and cell
hyperplasia which can lead to the development of pros-
tatic bladder outlet obstruction (BOO) and Lower
Urinary Tract Symptoms (LUTS); severe BPH leads to
deterioration of QoL and has relevant socio-economic
costs [2]. Historically BPH pathogenesis is linked to age
and androgens effect but more recently other factors
including family history, ethnicity, lifestyle behaviours
(reduced physical activity, cigarette smoking and high fat
diet) as well as metabolic diseases have been suggested to
play an important role [3, 4].
Metabolic syndrome(MetS) is a worldwide complex
disorder with high socioeconomic impact. MetS describes
the combination of several metabolic abnormalities,
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including central obesity, hypertension, dyslipidemia, insu-
lin resistance with compensatory hyperinsulinemia, and
glucose intolerance [5].
In the last 15 years several MetS components have
been closely associated with BPH, suggesting that MetS
has very heterogeneous clinical ramifications [6–8].
Although the relationship between BPH/LUTS and
MetS is still poorly understood, some findings suggest that
men with metabolic alterations faster develop [6] BPH or
are more likely to undergo BPH surgery, [7] supporting
the hypothesis that pathological alterations typical of MetS
also predispose to the development and progression of
BPH/LUTS. Indeed, in a recent meta-analysis, we demon-
strated that subjects with MetS have significantly higher
total and transitional zone prostate volume [9].
Aim of the present study is to evaluate the correlations
between the presence of MetS and each single MetS
parameter on prostate’s anthropometric measures in
men surgically treated for BPE.
Methods
Study population and design
Between January 2012 and September 2013, 379 consecu-
tive patients undergone prostatectomy for LUTS due to
large BPE, were prospectively enrolled in two tertiary re-
ferral centers. In both high volume referral centers, all pa-
tients included in this trial were managed by surgeons
skilled in diagnosis and treatment of LUTS/BPE. Informed
consent for the study was obtained from participants. The
study did not require any deviation of the Good Clinical
Practice so was conducted in accordance with the princi-
ples expressed in the Declaration of Helsinki.
In the study were included patients undergone simple
open prostatectomy (OP) or transurethral resection of
the prostate (TURP) for moderate to severe LUTS due
to BPE refractory to medical treatment. Patients with
previous history of prostate surgery, chronic medication
for prostatitis and/or urinary infection or bladder stone
or known malignant disease including prostate cancer
were excluded.
PSA values and prostate volume were evaluated during
the pre-hospitalization visits. Raw prostate volume was
calculated by suprapubic US (by using the “estimated el-
lipsoid volume” based on prostatic circumference), while
calculated prostate volume was measured by transrectal
US defining the antero-posterior (AP), the cranio-caudal
(CC) and the latero-lateral (LL) diameters through the
ellipsoid formula (D1xD2xD3xπ/6). OP and TURP were
performed as previously reported [10, 11]. LUTS were
measured by the International Prostate Symptom Score
(IPSS) and categorized as storage and voiding symptoms,
immediately before surgery and 6 to 12 months
postoperatively.
Definition of MetS
MetS was defined according to criteria defined by the
National Cholesterol Education Program-Third Adult
Treatment Panel (NCEP-ATPIII) [5, 12]. According these
criteria MetS is defined by the presence of at least 3 of the
following parameters: (1) waist circumference >102 cm;
(2) triglycerides ≥150 mg/dl or treatment for hypetrigly-
ceridemia, (3) HDL-Co < 40 mg/dl or treatment for re-
duced HDL-C, (4) blood pressure ≥ 130/85 mmHg or
current use of antihypertensive medications, and (5) fast-
ing blood glucose >110 mg/dl or previous diagnosis of
type 2 diabetes mellitus. All these items of MetS were con-
sidered individually (single parameters above vs below
cut-off points), as sum of continuous variables (one if the
single parameter is positive for MetS, zero if the single
parameter is negative), and combined according to MetS
(present or absent).
Statistical analyses
Unpaired two-sided Student’s t tests has been used for
comparisons between men with or without MetS, to
compare normally distributed parameters; in all other
cases, Mann-Whitney U test has been used. Correlations
have been assessed using Pearson’s or Spearman’s method
for normally or non-normally distributed data.
Moreover, we included significant data in a binary logis-
tic model regression to calculate the main determinant of
both raw and calculated prostate volume.
All the analyses were obtained with SPSS statistics
20.0 version for windows XP and a p <0.05 was consid-
ered statistically significant.
Results
Three-hundred seventy-nine non selected consecutive
men undergone surgical treatment of BPH were recruited
in two tertiary referral centers. One-hundred and forty
men (36.9%) were affected by MetS: preoperative patient’s
characteristics, stratified according to MetS diagnosis, are
reported in Table 1.
At univariate analysis raw prostate volume resulted
statistically related with systolic blood pressure and
serum trygliceride levels (r = 0.114, p = 0.035 and r = 0.126,
p = 0.013 respectively), while calculated prostate volume
resulted related with systolic blood pressure, serum trygli-
ceride levels and serum HDL levels (r = 0.179, p = 0.015
and r = 0.279, p < 0.001 and r = -0.303, p = p < 0.001 re-
spectively). The number of metabolic syndrome parame-
ters (0 to 5) and the presence of MetS (≥3/5 parameters)
were significantly correlated with the calculated prostate
volume (r = 0.244, p = 0.001 and r = 0.284, p < 0.001, re-
spectively). At age-adjusted multivariate analyses, systolic
blood pressure, serum HDL levels and the number of MetS
parameters were still statistically significantly correlated to
Gacci et al. BMC Urology  (2017) 17:22 Page 2 of 6
calculated prostate volume (r = 0.175, p = 0.014, r = -0.256,
p = 0.004 and r = 0.202, p = 0.007 respectively).
At the binary logistic regression (Table 2) considering
all the main determinants of prostate volume, including
age, BMI and use of 5-alpha-reductase inhibitors, MetS
resulted a statistically significant risk factor for large
(>60 cc) raw and calculated prostate volume (OR: 2.43
[95% CI: 1.444.09), p = 0.001 and OR: 4.28 [95% CI:
2.15–8.52), p < 0.001, respectively). A similar data was
obtained by using the median (>70 cc) raw volume (OR:
1.82 [95% CI: 1.08–3.09), p = 0.026).
The number of MetS parameters, resulted directly re-
lated with the calculated prostate volume (r = 0.244, p =
0.001), with the antero-posterior (r = 0.231, p = 0.002),
the cranio-caudal (r = 0.192, p = 0.009) and the latero-
lateral diameter (r = 0.171, p = 0.020, see Fig. 1). At the
age-adjusted multivariate analysis, including all the
diameters, only the AP diameter was significantly related
with the number of MetS parameters (r = 2.266, p = 0.025).
Furthermore, at the multivariate analysis based on sig-
nificant parameters that can influence prostatic growth,
the AP diameter was mainly correlated with HDL chol-
esterol (adjusted r for age, BMI and 5-ARIs: -0.3103, p =
0.002, see Fig. 2a), the CC diameter with triglycerides
(adjusted r for age, BMI and 5-ARIs: -0.191, p = 0.050,
see Fig. 2b) and the LL diameter with systolic blood
pressure (adjusted r for age, BMI and 5-ARIs: 0.154, p =
0.044, see Fig. 2c). However, the binary logistic regression
based on a median prostate diameters (AP = 40 mm,
CC = 45 mm, LL = 55 mm) adjusted for age, presence of
MetS, cigarette smoking and assumption of 5ARI, dem-
onstrated that low HDL Cholesterol was the main de-
terminant for the enlargements of all diameters and
consequently of the whole prostate volume (see Fig. 3).







Mean ± SD Mean ± SD p value
Demographic Age (years) 70.0 ± 7.4 68.5 ± 8.8 0.059
BMI (Kg/m2) 27.5 ± 3.5 25.8 ± 2.4 0.000
Smokers, Number, (%) 108 (77.1%) 171 (71.5%) 0.417
Prostate
Features
Prostate Volume (cc) 88.9 ± 59.1 77.8 ± 41.2 0.053
PSA (ng/mL) 3.9 ± 3.7 3.0 ± 3.2 0.062
Prostate treatment α-blockers, Number, (%) 103 (73.5%) 164 (68.6%) 0.200
5-ARI, Number, (%) 23 (16.4%) 33 (13.8%) 0.467
MetS parameters WC 104.6 ± 12.9 97.2 ± 7.3 0.000
Systolic BP 134.9 ± 14.7 131.3 ± 14.6 0.016
Diastolic BP 78.7 ± 8.5 76.7 ± 8.0 0.020
Glycemia 108.8 ± 37.1 94.1 ± 16.3 0.000
Triglyceride 149.8 ± 54.3 111.2 ± 42.7 0.000
HDL Cholesterol 41.5 ± 11.0 49.1 ± 7.4 0.000
Table 2 Binary logistic regression based on prostate volume≥ 60 cc vs. prostate volume < 60 cc. Age (< 65 vs. ≥ 65), BMI (< 25 kg/m2 vs.
≥ 25 kg/m2), Use of 5 ARI (no vs. yes), Presence of MetS (no vs. yes). OR Odds ratio. LL Lower Limit. UL Upper Limit
OR LL 95% CI for OR UL 95% CI for OR P value
RAW Prostate volume (N = 379)
Age 0.995 0.962 1.029 0.769
BMI 0.936 0.859 1.021 0.136
Use of 5ARI 1.054 0.541 2.056 0.877
Presence of MetS 2.430 1.441 4.095 0.001
CALCULATED Prostate volume (N = 187)
Age 0.972 0.930 1.015 0.200
BMI 0.854 0.760 0.959 0.008
Use of 5ARI 1.304 0.625 2.719 0.479
Presence of MetS 4.278 2.149 8.519 0.035
Italic=statistically significant
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Discussion
Metabolic syndrome (MetS) is a cluster of cardiovascular
and metabolic risk factors, associated with insulin re-
sistance [5]. For first in 1998 Hammarsten et al. [13]
described the possible relationship between some compo-
nents of MetS and BPH. In their study, annual transitional
prostate volume (TPV) growth rate was significantly
higher in BPH patients with MetS as compared with
those without MetS (1.019 ml/yr vs 0.699 ml/yr, re-
spectively). After this preliminary work, several authors
have documented a possible association between MetS
and BPH [14–16] but other authors didn’t confirm this
association [17]. Interestingly in a meta-analysis of the
available evidence we found that subjects with MetS had
significantly higher total prostate volume when compared
to those without MetS (+1.8 [95% CI: 0.74;2.87] ml;
p < 0.001) and these datas are in agreement to the present
one. The number of metabolic syndrome parameters (1 to
5) and the presence of MetS itself were related with the
prostate diameters as well as calculated prostate volume,
Fig. 1 Mean and 95% confidence interval of the mean of calculated prostate volume, antero-posterior (AP), cranio-caudal (CC) and latero-lateral (LL)
diameters, stratified according to the number of MetS parameters
Fig. 2 Scatterplot diagram of correlation between AP diameter and HDL Cholesterol, CC diameter and triglyceride, LL diameter and Systolic
blood pressure
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supporting a positive role for metabolic derangements in
the progression of BPE.
The pathogenetic mechanisms underlying the associ-
ation between MetS and BPH/LUTS are not completely
understood. Either clinical or experimental evidence sup-
ports the role of chronic inflammation as possible link
[18]. Although it has been known for at least 30 years that
inflammation directly or indirectly contributes to prostate
overgrowth, the role of impaired immunoresponse in BPH
pathogenesis has been recently accepted [18].
The effect of MetS to BPH pathogenesis probably
starts in early adulthood. Indeed, in a previous study on
a population of 222 relatively young men seeking medical
care for couple infertility, we found a significant associ-
ation among increasing BMI, higher prostate volume and
several sonographic features of prostate inflammation
[19]. In addition, higher BMI was significantly related to
higher value of IL-8 in seminal vesicle tissues, a reliable
surrogate marker of prostate inflammatory diseases [20].
In the same population we also found that MetS severity
was associated with increased prostate volume [21]. This
association indicates that the effect of MetS on prostate
growth begins very early and is detectable even in young
adulthood.
We recently developed a non-genomic animal model
of MetS, by exposing rabbits to a high-fat diet (HFD) for
twelve weeks [22]. Accordingly to the aforementioned
epidemiological clinical datas, severe prostatitis-like
syndrome, tissue remodeling [22, 23] and bladder dysfunc-
tion [22] were demonstrated in animal models of MetS
rabbits. Infiltration of inflammatory cells and fibrosis were
observed in prostate of MetS rabbits [24]. In addition, we
recently demonstrated the capacity of human myofibro-
blast prostatic cells to secrete several inflammatory cyto-
kines and chemokines, including IL-8, in response to
oxidized LDL (oxLDL) and insulin [25, 26]. These datas
indicate that different MetS features, mainly dyslipidemia
(oxLDL) and insulin resistance, could boost inflammation
and tissue-remodelling in BPH. Indeed in a multicentre
study on 271 consecutive men treated with simple
prostatectomy, the presence of MetS (in particular
MetS-associated dyslipidaemia) was associated with more
severe intraprostatic inflammation [27, 28]. Among
MetS components, reduced HDL cholesterol and elevated
triglycerides were significantly associated with elevated
prostate inflammatory score (IS) and CD45 positivity. Ac-
cording to these datas, the present article shows that re-
duced HDL cholesterol levels were inversely related to all
prostatic diameters. Dyslipidemia could have a detrimental
effect on prostate cells, boosting prostate inflammation,
a key factor in the development and progression of
BPH/LUTS. Interestingly, a retrospective population-based
cohort study on 2447 men aged 40–79 years, showed that
statins assumption was associated with a 6.5 to 7-years
delay in the new onset of moderate/severe LUTS/BPE [29].
Similarly, longitudinal datas from Health Professionals
Follow up Study (HPFS), a prospective database on
more than 18,000 US men, demostrated that men with
higher total and abdominal adiposity or who gained
weight were more likely to develop LUTS or experience
progressive LUTS [30].
Our prospective study has several limitations. Firstly,
we included men treated exclusively in two tertiary refer-
ral centers for BPH surgery: this population of men with
large prostate (≥80 cc), and marked reduction of urinary
flow parameters (Qmax < 9 mL/sec) may be very different
to that of the general community. Then, we didn’t adjust
our datas for additional parameters such as physical activ-
ity. Finally, we had data on calculated prostate volume
only for 187 patients.
Conclusions
In conclusion, present data along with recent evidences,
suggest that metabolic factors could play a crucial role
in the pathogenesis of LUTS/BPH. Further interventional
studies are needed to prove the potential effect of dys-
lipidemia treatment on LUTS/BPH, and in particular
on prostate enlargement.
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